PP
ODT

PDT Partners’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

PDT Partners’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-46,900
Closed -$164K – 974
2021
Q2 		$164K Hold
46,900
– – 0.01% 730
2021
Q1 		$160K Sell
46,900
-454
-1% -$8.58K 0.01% 718
2020
Q4 		$909K Sell
47,354
-9,005
-16% -$139K 0.06% 339
2020
Q3 		$757K Buy
56,359
+50,310
+832% +$1.43M 0.05% 353
2020
Q2 		$256K Sell
6,049
-6,351
-51% -$206K 0.02% 553
2020
Q1 		$342K Sell
12,400
-2,500
-17% -$72.9K 0.03% 452
2019
Q4 		$484K Buy
+14,900
New +$462K 0.03% 425

Other funds holding ODT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PDT Partners's ODT Position: Q3 2021 in Review

PDT Partners sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q3 2021, closing a stake of 46,900 shares — an estimated $164K sold.

PDT Partners first reported a position in ODT in Q4 2019 and held it in 7 quarters. The position peaked at $909K in Q4 2020. 58 funds tracked by Wall St. Rank hold ODT as of Q3 2021.

  • PDT Partners reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • PDT Partners sold 46,900 Odonate Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $164K.
  • PDT Partners first reported a position in Odonate Therapeutics, Inc. Common Stock in Q4 2019 and held it in 7 quarters.
  • PDT Partners's Odonate Therapeutics, Inc. Common Stock position peaked at $909K in Q4 2020.
  • 58 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q3 2021.

Based on PDT Partners's 13F filing for Q3 2021, filed 15 Nov 2021.